摘要
凝血功能異常及血栓事件是COVID-19常見的併發症。COVID-19感染造成局部及全身發炎反應，引起微血管內皮細胞凋亡，繼而誘發凝血活性及血小板活化，造成血栓病變。肺部微血管栓塞引起的惡性循環，是進展到呼吸衰竭或呼吸窘迫症候群的重要因素。臨床上，抗凝血藥物的使用是討論的焦點，包括哪些病人需要使用、使用的劑量及相關的出血風險等。這篇文章將介紹COVID-19相關凝血功能異常的臨床表現、病生理機轉、臨床試驗結果、及治療建議。
參考文獻
Yang W, Kandula S, Huynh M, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis 2021;21:203-12.
Leentjens J, van Haaps TF, Wessels PF, et al. COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year. The Lancet Haematology 2021;8:e524-33.
Nopp S, Moik F, Jilma B, et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020;4:1178-91.
Smilowitz NR, Subashchandran V, Yuriditsky E, et al. Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. Am Heart J 2021;231:93-5.
Salisbury R, Iotchkova V, Jaafar S, et al. Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv 2020;4:6230-39.